Drug Details

General Information of the Drug (ID: DR8801)
Name
Ibandronate
Synonyms
Ibandronic Acid; Ibandronate; 114084-78-5; Bondronat; Boniva; Bonviva; (1-Hydroxy-3-(methyl(pentyl)amino)propane-1,1-diyl)diphosphonic acid; UNII-UMD7G2653W; Bondenza; CHEMBL997; [1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphonic acid; UMD7G2653W; Phosphonic acid, [1-hydroxy-3-(methylpentylamino)propylidene]bis-; {1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl}phosphonic acid; Phosphonic acid, (1-hydroxy-3-(methylpentylamino)propylidene)bis-; Acid ibandronico; BFQ; Ibandronic acid [INN:BAN]; Bisphosphonate 2; [1-hydroxy-3-[methyl(pentyl)amino]-1-phosphono-propyl]phosphonic acid; Ibandronic acid (INN); SR-05000001496; (1-Hydroxy-3-(methylpentylamino)propylidene)diphosphonic acid; 1-hydroxy-3-(methylpentylamino)propylidene bisphosphonic acid; [1-HYDROXY-3-(METHYL-PENTYL-AMINO)-1-PHOSPHONO-PROPYL]-PHOSPHONIC ACID; SCHEMBL9183; C9H23NO7P2; GTPL3059; JMC515594 Compound 53; DTXSID5048340; BDBM12577; HY-B0515A; HMS2090A13; ACT05527; BCP13798; ZINC1533877; AC-521; MFCD00868772; AKOS015855723; DB00710; NSC 722623; AS-12948; FT-0602640; FT-0670253; D08056; M-1207; AB01275485-01; 084I785; Q166825; J-003052; SR-05000001496-1; SR-05000001496-2; BRD-K08681769-323-01-1; 1-hydroxy-3-(methyl(pentyl)amino)propane-1,1-diyldiphosphonic acid; {1-hydroxy-3-[methyl(pentyl)amino]propane-1,1-diyl}bis(phosphonic acid); Phosphonic acid, P,P'-[1-hydroxy-3-(methylpentylamino)propylidene]bis-
    Click to Show/Hide
Molecular Type
Small molecule
Disease Osteoporosis [ICD-11: FB83] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 4.1 +/- 2.6 mcg/L
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1.1 +/- 0.6 h
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability
Bioavailability
The bioavailability of drug is 0.63%
Clearance
The total clearance of drug is 84-160 mL/min
Elimination
55% of drug is excreted from urine in the unchanged form
Half-life
The concentration or amount of drug in body reduced by one-half in 37 - 157 hours
Metabolism
The drug is not metabolised
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.13063 micromolar/kg/day
Unbound Fraction
The unbound fraction of drug in plasma is 0.15%
Vd
The volume of distribution (Vd) of drug is 90-368 L
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C9H23NO7P2
PubChem CID
60852
Canonical SMILES
CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O
InChI
1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)
InChIKey
MPBVHIBUJCELCL-UHFFFAOYSA-N
CAS Number
CAS 114084-78-5
TTD Drug ID
D08SJZ
DrugBank ID
DB00710
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Farnesol      Mosla chinensis     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model LNCaP CVCL_0395 Prostate carcinoma Homo sapiens
PC-3 CVCL_0035 Prostate carcinoma Homo sapiens
                    Experimental
                    Result(s)		 Ibandronate effectively inhibits growth of prostate cancer cell lines via inhibition of the farnesyl-IPP-synthase and exhibits synergistic effects with docetaxel.
Target and Pathway
Target(s) Geranyltranstransferase (FDPS)  Molecule Info  [3]
BioCyc Superpathway of geranylgeranyldiphosphate biosynthesis I (via mevalonate) Click to Show/Hide
2 Superpathway of cholesterol biosynthesis
3 Trans, trans-farnesyl diphosphate biosynthesis
4 Geranylgeranyldiphosphate biosynthesis
KEGG Pathway Terpenoid backbone biosynthesis Click to Show/Hide
2 Metabolic pathways
3 Biosynthesis of antibiotics
4 Influenza A
5 HTLV-I infection
NetPath Pathway TCR Signaling Pathway Click to Show/Hide
Panther Pathway Cholesterol biosynthesis Click to Show/Hide
Pathwhiz Pathway Steroid Biosynthesis Click to Show/Hide
Reactome Cholesterol biosynthesis Click to Show/Hide
2 Activation of gene expression by SREBF (SREBP)
WikiPathways Activation of Gene Expression by SREBP (SREBF) Click to Show/Hide
2 SREBP signalling
3 Cholesterol Biosynthesis
References
Reference 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3059).
Reference 2 Differential effects of ibandronate, docetaxel and farnesol treatment alone and in combination on the growth of prostate cancer cell lines. Acta Oncol. 2011 Jan;50(1):127-33.
Reference 3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
 Download Picture         KEGG Link